These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 10942463)

  • 1. Optimal pregnancy outcome in a minimal-stimulation in vitro fertilization program.
    DeVane GW; Gangrade BK; Wilson R; Loy RA
    Am J Obstet Gynecol; 2000 Aug; 183(2):309-13; discussion 313-5. PubMed ID: 10942463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Minimal precycle testing and ongoing cycle monitoring for in vitro fertilization and fresh pre-embryo transfer do not compromise fertilization, implantation, or ongoing pregnancy rates.
    Strawn EY; Roesler M; Rinke M; Aiman EJ
    Am J Obstet Gynecol; 2000 Jun; 182(6):1623-8. PubMed ID: 10871488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ovarian response and pregnancy outcome in poor-responder women: a randomized controlled trial on the effect of luteinizing hormone supplementation on in vitro fertilization cycles.
    Barrenetxea G; Agirregoikoa JA; Jiménez MR; de Larruzea AL; Ganzabal T; Carbonero K
    Fertil Steril; 2008 Mar; 89(3):546-53. PubMed ID: 17531989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of luteal estradiol patch and gonadotropin-releasing hormone antagonist suppression protocol before gonadotropin stimulation versus microdose gonadotropin-releasing hormone agonist protocol for patients with a history of poor in vitro fertilization outcomes.
    Weitzman VN; Engmann L; DiLuigi A; Maier D; Nulsen J; Benadiva C
    Fertil Steril; 2009 Jul; 92(1):226-30. PubMed ID: 18675961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short coasting of 1 or 2 days by withholding both gonadotropins and gonadotropin-releasing hormone agonist prevents ovarian hyperstimulation syndrome without compromising the outcome.
    Moon HS; Joo BS; Moon SE; Lee SK; Kim KS; Koo JS
    Fertil Steril; 2008 Dec; 90(6):2172-8. PubMed ID: 18439601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of poor responders: can outcomes be improved with a novel gonadotropin-releasing hormone antagonist/letrozole protocol?
    Schoolcraft WB; Surrey ES; Minjarez DA; Stevens JM; Gardner DK
    Fertil Steril; 2008 Jan; 89(1):151-6. PubMed ID: 17482177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of outcomes and direct cost between minimal stimulation and conventional protocols on ovarian stimulation in in vitro fertilization.
    Sophonsritsuk A; Choktanasiri W; Weerakiet S; Rojanasakul A
    J Obstet Gynaecol Res; 2005 Oct; 31(5):459-63. PubMed ID: 16176518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical outcome of patients with follicular development retardation by prolonged duration of gonadotropin administration for in vitro fertilization].
    Chen SL; Sun L; Kong LH; Li L; Li J; Zhu L; Gao TM; Xing FQ
    Zhonghua Fu Chan Ke Za Zhi; 2007 Aug; 42(8):526-9. PubMed ID: 17983490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized controlled trial of increasing recombinant follicle-stimulating hormone after initiating a gonadotropin-releasing hormone antagonist for in vitro fertilization-embryo transfer.
    Propst AM; Bates GW; Robinson RD; Arthur NJ; Martin JE; Neal GS
    Fertil Steril; 2006 Jul; 86(1):58-63. PubMed ID: 16753156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A preliminary study on reduced dose (33 or 25 microg) gonadotropin-releasing hormone agonist long protocol for multifollicular ovarian stimulation in patients with high basal serum follicle-stimulating hormone levels undergoing in vitro fertilization-embryo transfer.
    Ku SY; Choi YS; Jee BC; Suh CS; Choi YM; Kim JG; Moon SY; Kim SH
    Gynecol Endocrinol; 2005 Oct; 21(4):227-31. PubMed ID: 16316845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Research on the protocol of limited ovarian stimulation to prevent ovarian hyperstimulation syndrome].
    Zhu YM; Gao HJ; He RH; Huang HF
    Zhonghua Fu Chan Ke Za Zhi; 2006 Nov; 41(11):740-4. PubMed ID: 17327030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Controlled ovarian hyperstimulation in women > or = 40 years old undergoing IVF-ET: mid-luteal versus early follicular (flare-up) GnRH analog regimens.
    Borini A; Trevisi MR; Bafaro MG; Cattoli M; Bianchi L; Flamigni C
    Acta Eur Fertil; 1995; 26(2):59-61. PubMed ID: 9098461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Methods and results of in-vitro fertilisation in the Netherlands in the years 1983-1994].
    De Boer EJ; Van Leeuwen FE; Den Tonkelaar I; Jansen CA; Braat DD; Burger CW
    Ned Tijdschr Geneeskd; 2004 Jul; 148(29):1448-55. PubMed ID: 15326650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blastocyst-stage embryo transfer in patients who failed to conceive in three or more day 2-3 embryo transfer cycles: a prospective, randomized study.
    Levitas E; Lunenfeld E; Har-Vardi I; Albotiano S; Sonin Y; Hackmon-Ram R; Potashnik G
    Fertil Steril; 2004 Mar; 81(3):567-71. PubMed ID: 15037404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reducing the dose of human chorionic gonadotropin in high responders does not affect the outcomes of in vitro fertilization.
    Schmidt DW; Maier DB; Nulsen JC; Benadiva CA
    Fertil Steril; 2004 Oct; 82(4):841-6. PubMed ID: 15482757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The optimal length of 'coasting protocol' in women at risk of ovarian hyperstimulation syndrome undergoing in vitro fertilization.
    Nardo LG; Cheema P; Gelbaya TA; Horne G; Fitzgerald CT; Pease EH; Brison DR; Lieberman BA
    Hum Fertil (Camb); 2006 Sep; 9(3):175-80. PubMed ID: 17008270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gonadotropin-releasing hormone agonist/antagonist conversion with estrogen priming in low responders with prior in vitro fertilization failure.
    Fisch JD; Keskintepe L; Sher G
    Fertil Steril; 2008 Feb; 89(2):342-7. PubMed ID: 17562336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fertilization, embryo development, and clinical outcome of immature oocytes from stimulated intracytoplasmic sperm injection cycles.
    Shu Y; Gebhardt J; Watt J; Lyon J; Dasig D; Behr B
    Fertil Steril; 2007 May; 87(5):1022-7. PubMed ID: 17261289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of retained embryos on pregnancy outcome in an in vitro fertilization and embryo transfer program.
    Vicdan K; Işik AZ; Akarsu C; Sözen E; Cağlar G; Dingiloğlu B; Tuncay G
    Eur J Obstet Gynecol Reprod Biol; 2007 Sep; 134(1):79-82. PubMed ID: 17343976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A controlled trial of natural cycle versus microdose gonadotropin-releasing hormone analog flare cycles in poor responders undergoing in vitro fertilization.
    Morgia F; Sbracia M; Schimberni M; Giallonardo A; Piscitelli C; Giannini P; Aragona C
    Fertil Steril; 2004 Jun; 81(6):1542-7. PubMed ID: 15193474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.